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The human immunodeficiency virus type 1 (HIV-1) auxiliary gene vif is essential for virus propagation in peripheral blood lymphocytes,
macrophages, and in some T-cell lines. Previously, it was demonstrated that Vif inhibits the autoprocessing of truncated HIV-1 Gag–Pol
polyproteins expressed in bacterial cells, and that purified recombinant Vif and Vif-derived peptides inhibit and bind HIV-1 protease (PR).
Here we show that Vif interacts with the N-terminal region of HIV-1 PR, and demonstrate that peptide derived from the N-terminal region of
PR abrogates Vif function in non-permissive cells. Specifically, we show that (i) Vif protein binds HIV-1 PR, but not covalently linked
tethered PR-PR; (ii) the four amino acids residing at the N terminus of HIV-1 PR are essential for Vif/PR interaction; (iii) synthetic peptide
derived from the N terminus of HIV-1 PR inhibits Vif/PR binding; and (iv) this peptide inhibits the propagation of HIV-1 in restrictive cells.
Based on these data, we suggest that Vif interacts with the dimerization sites of the viral protease, and that peptide residing at the N terminus
of PR abrogates Vif function(s).
D 2004 Elsevier Inc. All rights reserved.
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There is wide consensus that HIV-1Vif (virion
infectivity factor) is indispensable for establishing pro-
ductive HIV-1 infection in peripheral blood lymphocytes,
macrophages and some cell lines such as H9, Hut78
(non-permissive cells), but not in Sup T1 and CEM lines
(permissive cells) (Fisher et al., 1985, 1987; Kishi et al.,
1992; Lee et al., 1986; Sodroski et al., 1986; Strebel et
al., 1987). In the SCID-hu model, deletion of vif
significantly decreased infectivity and attenuated the
pathogenic potential of HIV-1, pointing to the pivotal
role of Vif in establishing infection in vivo (Aldrovandi0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: mkotler@cc.huji.ac.il (M. Kotler).and Zack, 1996; Desrosiers, 1992; Sova and Volsky,
1993). While the phenotype of the vif gene is clear, the
mechanism and location of Vif activity are still
controversial. One view holds that Vif interacts with
cellular factor(s) (Hassaine et al., 2001; Madani and
Kabat, 1998; Simon et al., 1998a, 1998b; Zimmerman et
al., 2002), while a second points at interaction of Vif
with viral components (for review see Baraz and Kotler,
2004). The findings that some, but not all cell lines,
require Vif for the production of infectious virus were
explained in two ways: permissive cells may express a
factor(s) that compensates for Vif (Borman et al., 1995;
Gabuzda et al., 1992), or alternatively, restrictive cells
possess a factor(s) that inhibits HIV-1 replication in the
absence of Vif (Hassaine et al., 2001; Madani and
Kabat, 1998; Simon et al., 1998a, 1998b; Zimmerman et
al., 2002). Thus, Vif may act either as a factor, which
facilitates virus production, or as a protein that neutral-
izes cell factors(s) with anti-viral activity.04) 261–270
Fig. 1. Schematic presentation of the chimeric proteases between HIV-1 and
ASLV. White and filled boxes indicate HIV-1 and ASLV protease,
respectively.
Fig. 2. Dose-dependent binding of proteases to Vif (A) and Vif to
proteases (B) in ELISA. Microwells were coated with 0.2 AM of purified
Vif, blocked with low fat milk for 2 h and subsequently incubated with 0,
25, 50, 100, and 200 nM of PR HIV-1 (.), PR HIV-1ASLV (o), PR ASLV
(n) and PR ASLVHIV-1 (5). Bound PRs were detected with rabbit anti-PR
primary antibody and alkaline phosphatase conjugated goat anti-rabbit
IgG secondary antibody. (B) Microwells were coated with 90 nM of PR
HIV-1 (.), PR HIV-1ASLV (o), PR ASLV (n), PR ASLVHIV-1 (5) and
BSA (E), incubated with low fat milk for 2 h and incubated with 0, 20,
40, 80, and 160 nM of purified Vif protein. The binding of Vif was
assessed with rabbit anti-Vif primary antibody and alkaline phosphatase-
conjugated goat anti-rabbit IgG secondary antibody. Results represent
average of three independent experiments.
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inhibitors (Hassaine et al., 2001; Madani and Kabat, 1998;
Zimmerman et al., 2002). Recently, Sheehy et al. (2002)
proposed that Vif neutralizes an intracellular virus inhibitor
expressed in non-permissive cells. They described the cell
factor CEM 15 which is responsible for immunization of
cells against vif-negative HIV-1. This CEM 15 protein is
intensively expressed in non-permissive, but not in permis-
sive cells. Moreover, expression of CEM 15 in permissive
cells renders them restrictive for replication of vif-negative
HIV-1. These results strongly suggest that Vif suppresses
the anti-viral activity of CEM 15 protein in restrictive cells
(Sheehy et al., 2002). Sequencing of this gene revealed that
CEM 15 is actually APOBEC3G, a member of the
APOBEC family of proteins, which are involved in RNA
editing and function by deaminating cytosine in RNA
(Harris et al., 2002; Jarmuz et al., 2002; Teng et al., 1993).
However, APOBEC3G, when expressed in Escherichia
coli, has been shown to act as a DNA mutator attributed to
dCYdU mutations (Harris et al., 2002). Several reports
showed that APOBEC3G induces G to A hypermutation in
newly synthesized viral DNA by deaminating dC to dU
within the retroviral minus (first) strand cDNA (Harris et al.,
2003; Mangeat et al., 2003; Yu et al., 2004; Zhang et al.,
2003). HIV-1 Vif expressed in the cells binds APOBEC3G,
leading to its ubiquitination and degradation via the
proteosome pathway (Conticello et al., 2003; Kao et al.,
2003; Mariani et al., 2003; Marin et al., 2003; Mehle et al.,
2004; Sheehy et al., 2003; Stopak et al., 2003; Yu et al.,
2003). According to this model, Vif eliminates the
APOBEC3G from cells, thus enabling the production of
infectious virus. However, this is not the sole mechanism
envisaged for Vif as a neutralizer of APOBEC3G. Mehle et
al. (2004) showed that Vif function(s) is still required in
cells expressing mutated inactive APOBEC3G, in order to
produce infective virus.
Several groups have previously demonstrated that Vif
interacts with viral components such as viral RNA, RT,
Gag–Pol, or protease (for review, see Baraz and Kotler,
2004). Vif-deficient particles produced by non-permissive
cells are distinguished from wt particles by several
criteria: these Vif-negative particles show non-homoge-nous packaging of the internal core, instead of the
normal dense cone-shaped core structure. Vif-deficient
virions are more susceptible to disruption by detergents,
high salt concentration, and buffers of various pH values
(Khan et al., 2002; Ohagen and Gabuzda, 2000). These
findings correlate with our model, suggesting interaction
of Vif with PR (Baraz et al., 2002; Blumenzweig et al.,
2002). According to this hypothesis, Vif appears to act as
a proteolytic regulator in non-permissive cells, directing
the initiation of precursor processing to the correct
location and timing, thus assuring production of mature
virions.
Retroviral protease, which is translated as part of a
large polyprotein, processes Gag and Gag–Pol precursors
and is responsible for virus maturation. The HIV-1 PR is
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amino acid units. The active form of PR HIV-1 is a
homodimer, in which its four termini form an anti-
parallel h-sheet interface (Meek et al., 1989; Pearl and
Taylor, 1987). Dimerization of the enzyme occurs while
PR is still a part of the Gag–Pol precursor, facilitating the
autoprocessing of the polyproteins resulting in virus
maturation (Krausslich, 1991). Expression of Vif with
truncated Gag–Pol fusion polyproteins in bacterial cells
inhibits processing of precursors. Recombinant Vif
prevents degradation of synthetic peptide by PR (Kotler
et al., 1997), and inhibits PR-mediated Pr55Gag process-
ing in vitro (Bardy et al., 2001). The inhibitory activity
of Vif was mapped to region aa 78–98 (Baraz et al.,
1998; Friedler et al., 1999; Kotler et al., 1997; Potash et
al., 1998). Baraz et al. (2002) located the interaction
between Vif and PR to the N terminus of PR and central
region of Vif.
The results of the experiments described in this report
indicate that the 4 amino acid residues residing at the N
terminus of HIV-1 PR are essential for Vif/PR inter-
action, verifying the specific interaction between Vif and
PR N termini. Moreover, we demonstrate that a peptide
derived from the PR N terminus inhibits Vif function
and halts the production of infectious particles in
restrictive cells.Results
Binding of PRs to Vif
Previously, we suggested that Vif hampers the h-sheet
structure formed by the termini regions of the four strands of
the dimeric HIV-1 PR (Blumenzweig et al., 2002). In order
to support the finding that Vif directly interacts with the N
terminus of HIV-1 PR, we constructed chimeric proteasesFig. 3. Inhibition of the binding of Vif to PR by PR in ELISA. Microwells were coa
blocked with low fat milk. Eighty nanomolars of Vif protein were added, following
was assessed as described in legend of Fig. 2B. Results represent average of threbetween HIV-1 and ASLV PRs. In these chimeric mole-
cules, the termini of HIV-1 and ASLV PRs were replaced by
the four amino acid residues residing at the N and C termini
of ASLV and HIV-1 PRs, respectively (Fig. 1). Vif-coated
microwells were used in ELISA to determine whether the
wild type and the chimeric PRs bind to Vif. Fig. 2A clearly
shows that purified HIV-1 PR and the chimeric ASLVHIV-1
PR bind to Vif in a dose-dependent manner. On the other
hand, ASLV PR and HIV-1ASLV PR do not bind to the same
Vif-coated wells. Similar results were obtained by a
reciprocal experiment, where increasing amounts of Vif
were added to wild type and chimera PR-coated wells. Fig.
2B demonstrates that Vif molecules bind to HIV-1 and
ASLVHIV-1 PRs, but not to ASLV and HIV-1ASLV PRs. The
Vif/PRs binding is specific as PRs and Vif do not bind to
BSA coated microwells. The results of these experiments
strongly suggest that Vif interacts with the four amino acids
residing at the termini of HIV-1 PR.
The specificity of the binding of Vif to PRs was
confirmed by competitive experiments, in which PRs were
incubated with Vif prior to adding into the Vif-coated
microwells. Fig. 3 shows that pre-incubation with PR HIV-1
and PR ASLVHIV-1, but not with PR HIV-1ASLV and PR
ASLV, inhibits binding of Vif to solid phase PR HIV-1 and
PR ASLVHIV-1.
The experiments described above did not enable us to
distinguish whether Vif interacts with the N or C termini of
HIV-1 PR. To resolve this question, we synthesized two
peptides, PR1–9 and PR94–99, corresponding of the N and
C termini of HIV-1 PR, respectively. Pre-incubation of Vif
with these peptides before addition to the PR-coated wells
shows that the PR1–9 peptide blocks the binding of Vif to
HIV-1 PR and ASLVHIV-1-PR in a dose-responsive manner.
In contrast, pre-incubation with the PR94–99 peptide does
not affect the binding (Fig. 4). Again, Vif did not bind to
ASLVand HIV-1ASLV PRs neither in the presence, nor in the
absence of these two peptides. These results suggest that Vifted with 100 nM of PR HIV-1, PR HIV-1ASLV, PR ASLV, or PR ASLVHIV-1,
pre-incubation with 100 nM of PRs for 18 h at 4 8C and the binding of Vif
e independent experiments.
Fig. 4. PR1–9 blocks the binding of Vif to PR HIV-1 and PR ASLVHIV-1. ELISA microwells were coated with 90 nM of PR HIV-1, PR HIV-1ASLV, PR ASLVor
PR ASLVHIV-1 and 150 nM of Vif protein was added following pre-incubation with the indicated amounts of PR1–9 and PR94–99 peptides for 18 h at 4 8C. Vif
was detected as explained in the legend to Fig. 2B. Results represent average of three independent experiments.
M. Hutoran et al. / Virology 330 (2004) 261–270264interacts with the conserved N-terminal region of PR.
Unfortunately, since the chimeras HIVASLV PR and
ASLVHIV-1 PR were catalytically inactive, inhibition tests
by Vif were not feasible.
Tethered PR does not bind the Vif molecule
If indeed Vif interacts with the N terminus of HIV-1 PR,
we would expect Vif not to bind to the tethered PR in which
the monomer molecules are covalently linked by a short
flexible hinged region head to tail (Krausslich et al., 1991).
The tethered PR, but not the natural enzyme is stable under
dissociated conditions. Fig. 5 demonstrates that unlike theFig. 5. Binding of HIV-1 PR and tethered PR-PR to Vif in ELISA.
Microwells were coated with 200 nM of Vif (n, 5) or BSA (., o),
incubated with increasing concentration of wt PR (n, .) or tethered PR-PR
(5, o). Bound proteases were detected as in the legend of Fig. 2A. Results
represent average of three independent experiments.wild type PR which binds Vif, purified recombinant tethered
PR does not interact with Vif. This result provides additional
evidence that Vif binds to the PR termini and consequently
interferes with its dimerization state. The finding that the
Vif-derived peptide (Vif78–98) does not inhibit the hydrol-
ysis of synthetic peptide by the tethered PR (Blumenzweig
et al., 2002) is in accordance with this model, suggesting
that Vif hampers PR dimerization.
PR-derived peptide arrests virus production in
non-permissive cells
Vif is absolutely required for the production of infectious
virus in non-permissive cells (Fisher et al., 1987; Kishi et
al., 1992; Lee et al., 1986; Sodroski et al., 1986; Strebel et
al., 1987). The experiments described above suggest that
PR1–9 blocks the binding of Vif to PR, probably as they
compete for a common binding site. If PR1–9/Vif binding
blocks Vif function, then the PR1–9 peptide would inhibit
production of infectious virus in restrictive, but not in
permissive cells. To examine this possibility, we infected H9
and Sup T1 cells with wt HIV-1 at m.o.i. 1. One hour post-
infection, the cells were suspended in a medium containing
50 AM of PR1–9 or PR94–99 peptides. The media were
collected during 10 days post-infection, and the amount of
virus produced by these cells was estimated by measuring
the amounts of p24 CA released by the cells; the titer of the
infectious virus was determined by infection of HeLa CD4+
cells. The results clearly show that the PR1–9 peptide, but
not PR 94-99 reduced the virus propagation in H9 cells,
rather than in Sup T1 cells (Fig. 6A). On the other hand, the
production of p24 by Sup T1 cells infected with wild type or
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the HIV-1 PR termini, suggesting that the PR1–9 blocks the
Vif function(s).
Kinetic of virus production by H9 and Sup T1 cells
treated with the peptides derived from the PR termini verify
that only PR1–9, but not PR94–99 inhibits the production of
infectious particles from H9 rather than from Sup T1 cells
(Fig. 6B). The ratio between the amounts of p24 and
infectious units produced by the permissive and restrictive
cells following treatment with PR1–9 and PR94–99 is
presented in Fig. 6C. The results indicate that the PR1–9-
treated H9 cells infected with HIV-1 do not merely reduce
the amount of particles released from these cells, but that the
proportional amount of infectious particles to the viral
proteins in this preparation is low.
PR1–9 peptide reduces virus production by permissive cells
expressing APOBEC3G
Expression of APOBEC3G in the permissive 293T cells
turns them restrictive for DVif virus propagation. Thus, the
replication of HIV-1 in these cells becomes Vif-dependent
(Sheehy et al., 2002). We were interested therefore to assess
whether treatment of APOBEC3G transfected 293T cells
with PR1–9 reduced the production of viruses. To this end,
293T cells were co-transfected with vectors expressing
either wild type or DVif HIV-1 together with APOBEC3G.
The transfected cultures were treated with the peptides
derived from the HIV-1 PR termini and the titer of the
viruses produced by these cells was determined by MAGI
assay. Treatment of cells with the PR1–9 peptide reduced
the titer of infectious virus by 3 orders, while the same cells
treated with the PR94–99 peptide produced large amounts
of infectious virus similar to the untreated cells (Fig. 7A).
However, analysis of extracts prepared from these cells by
Western blot, did not reveal any alteration in the amounts of
APOBEC3G in 293T cells treated with PR-derived peptides
(data not shown). The PR-derived peptides did not affect the
production of infectious particles from cells transfected with
vectors expressing wild type, or DVif viruses (Figs. 7B and
C). The control cells transfected with vectors expressing the
DVif virus and APOBEC3G vectors did not produce any
infectious particles (data not shown).Discussion
Although the accumulated data on Vif appear to be
conflicting, it seems that Vif serves as a multi-functional
protein. This assumption is supported by the findings that
Vif interacts with viral and cellular proteins, and by
demonstrating that many point mutations inserted along the
Vif molecule abolish its activity and alter the virus
phenotype to vif-negative (Simon et al., 1999). Previously,
we proposed that Vif regulates PR activity in the late phase
of virus multiplication, and demonstrated that Vif binds PRand inhibits its activity in bacterial and in several cell-free
systems (Baraz et al., 1998; Friedler et al., 1999; Kotler et
al., 1997; Potash et al., 1998). However, others and we
failed to demonstrate that the DVif viruses released from
non-permissive cells contain non-processed precursor
proteins (Bardy et al., 2001; Bouyac et al., 1997; Fouchier
et al., 1996; Khan et al., 2001). On the other hand, the
DVif viruses have a lower density and are more sensitive
to detergents and low pH, suggesting alteration in the
structure and/or composition of the DVif virions (Ohagen
and Gabuzda, 2000).
Here, we report that the HIV-1 Vif protein interacts
directly with the viral PR in a cell-free system, and that the 4
terminal amino acids of PR are essential for this interaction.
The HIV-1 Vif/PR binding is specific since Vif does not
interact with ASLV PR, chimeric HIV-1ASLV PR, tethered
PR-PR or with BSA. Although the use of ELISA did not
allow us to determine the binding and the binding-inhibition
coefficients, we demonstrated that PR1–9 inhibits the
interaction of Vif/PR in a dose-responsive manner, suggest-
ing that PR1–9 competes with PR on the Vif binding site.
Peptide PR1–9, which represents the 9 amino acids residing
at the N terminus of the enzyme, inhibits the interaction of
Vif/PR in a cell-free system and decreases the production of
infectious HIV-1 in the non-permissive H9 cell line. More-
over, this peptide also reduces the production of infectious
particles from the permissive 293T cells co-transfected with
vectors expressing APOBEC3G and viral genomes. It is of
interest that PR1–9 inhibits the production of infectious virus
from 293T cells co-transfected with APOBEC3G and HIV-1
vectors more efficiently than in HIV-1 infected H9 cells.
Previously, it was demonstrated that Vif/APOBEC3G
interaction neutralizes the natural HIV-1 inhibitor APO-
BEC3G, enabling the production of infectious particles in
restrictive cells. Based on these and our results, we
hypothesize that PR1–9 binds to Vif and interferes with the
interaction of Vif/APOBEC3G. In accordance with these
findings, it can be expected that PR1–9 treatment would
reduce the degradation of APOBEC3G in the transfected
293T cells. However, by using Western blot experiments, we
could not demonstrate any effect on APOBEC3G induced by
the PR-derived peptides. We suggest therefore that elimi-
nation of APOBEC3G by proteasome degradation is not the
sole function of Vif and it is not an absolute prerequisite for
production of infectious virus. The mechanism by which
PR1–9 abrogates Vif function as an APOBEC3G neutralizer
is as yet unknown and is presently under investigation in our
laboratory.
The region 84–98 in Vif contains a motif similar to the
consensus sequence of the PR C terminus, which interacts
with the PR N-terminus in establishing the 4-strand h-sheet
structure (Baraz et al., 2002). In line with these findings, we
assume that PR1–9 blocks this active site in Vif. It is not yet
known whether PR1–9 competes with APOBEC3G on the
same binding site, or the binding of PR1–9 to Vif induces
structural modification, which hampers the Vif/APOBEC3G
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Fig. 6. PR1–9 peptide inhibits HIV-1 replication in H9 cells. SupT1 and H9
cells were incubated with 50 AM PR1–9 and PR 94–99 peptide for 1 h and
then infected with HIV-1 wild type and DVif HIV-1 at multiplicity of
infection 1. Cultured fluids were replaced every 48 h with fresh medium
containing the peptides. Samples of media from days 1, 3, 6, and 10 were
taken and analyzed for the presence of viral particles by p24 test (A) and for
their infectivity by MAGI assay (B). Results represent average of three
independent experiments. (C) Ratio of infectivity (number of IU) to amount
of p24 CA on day 10.
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agents due to their susceptibility to proteolysis, poor
bioavailability, unfavorable pharmacokinetics, and rapid
clearance. Presently, the lead PR1–9 peptide is being
converted into small peptidomimetics to examine the
potential of these lead compounds to become stable selective
novel type HIV-1 Vif inhibitors.Fig. 7. PR1–9 peptide inhibits production of HIV-1 in 293T cells
transfected with APOBEC3G, HIV-1 wt and HIV-1 DVif containing
plasmids were co-transfected with plasmid containing APOBEC3G to
293T cells. Samples of media from days 2, 4, and 7 were taken and
analyzed for the infectivity of viral particles by MAGI assay. (A) 293T
co-transfected with HIV-1 wt+ APOBEC3G. (B) 293T transfected with
HIV-1wt. (C) 293T transfected with HIV-1 DVif. Results represent
average of three independent experiments.Materials and methods
Cells
The T-lymphocyte cell lines Sup T1 and H9, provided by
the NIH Reagent Program (Division of AIDS, NIAID, NIH,
USA), were grown in RPMI 1640 medium (Biological
Industries, Beit Haemek, Israel). Adherent cell line 293T
was kindly supplied by Dr. E. Bacharach (Tel Aviv
University, Israel) and HeLa–CD4+h-gal cells were
obtained through the NIH Reagent Program (Division of
AIDS, NIAID, NIH, USA). The adherent cell lines were
cultivated in Dulbecco’s modified Eagle’s medium
(DMEM) as a sub confluent monolayer. HeLa–CD4+h-gal
cells were maintained in the presence of 200 Ag/ml G418
and 100 Ag/ml Hygromycin B (Calbiochem, La Jolla, CA,
USA). RPMI 1640 and DMEM media were supplemented
with 10% fetal calf serum (FCS), 100 U/ml penicillin, 100
U/ml streptomycin and 2 mM l-glutamine (Biological
Industries).
Bacterial cells
E. coli BL21 cells (DE3) were grown in Luria–Bertini
(LB) medium in the presence of 100 Ag/ml chloramphe-nicol (Sigma, Israel), while E. coli DH5aa´ strain was
grown in antibiotic-free LB. E. coli MC 1061 cells were
grown in LB medium with 50 Ag/ml tetracycline
(Sigma).
Viruses
HIV-1 wild type was generated by transfection (Cullen,
1987) of 293T cells with pSVC21 plasmid containing
full-length HIV-1HXB2 viral DNA (Ratner et al., 1985).
Both wt and DVif viruses were harvested 48 and 72 h
post-transfection and the viruses were stored at 75 8C
until titration.
293T cells were transfected with pSVC21DVif (Gabuzda
et al., 1992) or with pSVC21DVif and pcDNA-APO3G (Kao
et al., 2003).
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Titration of HIV-1 was carried out by the multinuclear
activation of a galactosidase indicator (MAGI) assay, as
described by Kimpton and Emerman (1992). Briefly, HeLa–
CD4+h-gal cells were transferred into 96-well plates at 15 
103 cells per well. On the following day, the cells were
infected with 50 Al of serially diluted virus in the presence of
20 Ag/ml of DEAE-dextran (Pharmacia, Sweden). Two days
post-infection, cultured cells were fixed with 1% form-
aldehyde and 0.2% glutaraldehyde in PBS. Following
intensive wash with PBS, cells were stained with a solution
of 4 mM potassium ferrocyanide, 4 mM potassium ferricya-
nide, 2 mM MgCl2 and 0.4 mg/ml of X-Gal (Ornat, Israel).
Blue cells were counted under a light microscope at a
magnification of 200.
p24 assay
This was performed by using an HIV-1 p24 antigen
capture assay kit (SAIC, AIDS Vaccine Program, Frederic,
MD), in accordance with the standards and instructions
supplied by the manufacturers.
Infection of cultured cells
Cultured lymphocytes (1106–5 106) were centrifuged
for 5 min at 2000 rpm, the supernatant was aspirated and the
cells resuspended in 0.2–0.5 ml of medium containing virus
at m.o.i. 0.1 to 5. Following absorption for 1 h at 37 8C, the
cells were washed to discard unbound virus and incubated for
an additional 1–12 days.
Construction of chimeric PRs
The plasmids expressing the chimeric HIV-1 and Avian
sarcoma leucosis virus (ASLV) PRs (Fig. 1) were con-
structed by replacing the DNA fragments encoding for the
reciprocal 4 aa residing at the PRs termini. pUC12N plasmid
bearing the HIV-1 PR (Kotler et al., 1988a) was used as a
template to amplify the HIV-1ASLV PR by using primers (5V-
CCCGGGCCATGGTCCTCGCGATGACTCTTTGG-
CAACGACCC-3V and 5V-CCCGGGAAGCTTA-
TAAATTTGTCAAGCAACCAATCTGAGTCAA-3V)
containing the sequences encoded for the ASLV-PR termini
(underlined). The amplified DNA fragment was cleaved by
NcoI and HindIII and inserted into pUC12N. The chimeric
PR DNA fragment was rescued from the pUC12N by
cleavage with NcoI and HindIII restriction enzymes,
inserted into the pT5 vector for expression in E. coli
BL21 strain (Baraz et al., 2002).
Primers (5V-CCCGGGGGATCCATGCCTCAGATCA-
CAATGGAACATAAAGAT-3V and 5V-CCCGGGAAGCT-
TAAAAATTTAATGTGCGGAGCCCTAGGCCC-3V) con-
taining the DNA sequences encoding for the 4 aa residing
in the HIV-1 PR (Fig. 1) (underlined) were used to achieveASLVHIV-1 chimeric protein by amplification of the pEV
containing the DNA sequence of ASLV PR (Kotler et al.,
1992). The amplified DNA fragment was cleaved by
BamHI and HindIII and inserted into pUC12N and then
into pT5 plasmid as described above. The expression of PRs
inserted into pT5 was induced by 1 mM of IPTG (Isopropyl
h-d-galactopyranoside), while the ASLV PR expressed by
pEV was produced following a temperature shift to 42 8C
(Kotler et al., 1988b, 1992).
Peptides
Peptides were synthesized using the solid phase
peptide synthesis (SPPS) method, on an ABI peptide
synthesizer model 433A on Rink amide resin (loading 0.5
nmol/g) by standard Fmoc chemistry. HIV-1 PR-derived
peptides are: PR1–9 PQITLWQRP-NH2 and PR94–99
GCTLNF-NH2.
Purification of viral proteases
ASLV PR was purified from E. coli MC 1061 bacterial
cells, as previously described (Friedler et al., 1999; Kotler et
al., 1988b). HIV-1 PR, HIV-1ASLV PR and ASLVHIV-1 PR
were purified according toDr.Konvalinka’smethod (personal
communication) as previously described (Baraz et al., 1998).
Tethered covalently linked dimer of HIV-1 PR (Krausslich et
al., 1991) was expressed from pET11PR-PR plasmid (kindly
supplied by Dr. Konvalinka, Institute of Organic Chemistry
and Biochemistry, Praha, Czech Republic) in E. coli BL21
and purified as described above for HIV-1 PR.
HIV-1 Vif purification
The pD10 plasmid, which encodes for HIV-1HXB2 Vif
(Yang et al., 1996), was kindly provided by Dr. Gabuzda
(Dana-Farber Cancer Institute, Boston, MA). The Vif was
expressed in E. coli MC-1061 and purified as previously
described (Yang et al., 1996).
Vif/PR binding assay
Vif/PR binding assay was performed as previously
described Baraz et al. (2002). In brief, the wells of
ELISA plate were coated with of 200 nM Vif, 90 nM PR
or 200 nM BSA in 200 Al of 0.1 M NaCl and 50 mM
sodium phosphate buffer (pH 7.4).
Following blocking with low-fat milk, increasing
concentrations of PR (20–250 nM) or Vif (20–150 nM)
in PBS were loaded into the wells and incubated for 1 h
in room temperature. In the competitive binding experi-
ments, increasing concentrations of PR-derived peptides
were pre-incubated for 18 h at 4 8C with Vif or PR
proteins respectively, before loading into the coated wells.
The plates were extensively washed and the amounts of
Vif or PR bound to the coated wells were determined by
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(diluted 1:1000), respectively. The binding was deter-
mined by using alkaline phosphatase-conjugated goat
anti-rabbit IgG diluted 1:10000 (Sigma). The bound PR
or Vif were quantified with an ELISA reader (Dynatech
MR5000) at 405 nm following addition of substrate
p-nitro phenyl phosphate (Sigma).
Antibodies
Anti HIV-1 PR and anti ASLV PR polyclonal antibodies
were prepared by immunizing rabbits with three injections
of purified recombinant proteases. Anti-CA and anti-Vif
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jugated goat-anti-rabbit IgG and horseradish peroxidase
conjugated goat anti-rabbit sera were purchased from
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